Print this page
-
A Dose Finding Study of CycloSam? (153Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewings Sarcoma, and other solid tumor(s) to the bone all eligible).
Protocol: 052201Principal Investigator:
- Sanjay Goel (Rutgers University)
Applicable Disease Sites: Breast
Prostate
Lung
Any Site -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Bones and Joints
Lung -
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies.
Protocol: 052202Principal Investigator:
- Eugenia Girda Assistant Professor GYN (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma.
Protocol: 032208Principal Investigator:
- Anupama Nehra M.D. (Rutgers University)
Applicable Disease Sites: Lung -
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).
Protocol: 032002Principal Investigator:
- Matthew Deek (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm.
Protocol: 032006Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung